Topics:

Study to Measure Impact of ProstaScint Imaging in Prostate Cancer

Study to Measure Impact of ProstaScint Imaging in Prostate Cancer

PRINCETON, New Jersey—Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer. 

ProstaScint is a radiolabeled monoclonal antibody that targets prostate specific membrane antigen. In the study, the specific areas of greatest tumor burden within the prostate, identified by the ProstaScint image, will receive boosted doses of radiation via IMRT.

 
Loading comments...
Please Wait 20 seconds or click here to close